Crofelemer Cuts Parenteral Support 48% in MVID, 40% in SBS Trials
JAGX•Jaguar Health’s high-dose oral crofelemer cut normalized weekly parenteral support by 48% in a microvillus inclusion disease patient and by 40% in short bowel syndrome cases after 12+ months, with no significant clinical or lab abnormalities. The company plans Breakthrough Therapy designation and to file an NDA by mid-2027.
1. Presentation Highlights
Jaguar Health’s affiliate Napo presented crofelemer adjunctive oral therapy data at the 58th ESPGHAN meeting focusing on pediatric patients with microvillus inclusion disease and short bowel syndrome with intestinal failure.
2. Clinical Efficacy Results
Data showed that after more than 12 months of high-dose oral dosing, weekly parenteral support normalized to body weight fell by up to 48% in a MVID patient and up to 40% in two SBS patients.
3. Safety and Tolerability
Participants experienced no significant clinical or laboratory abnormalities throughout the longer-term treatment period, underlining crofelemer’s tolerability in these vulnerable pediatric populations.
4. Regulatory and Development Plans
Jaguar plans to pursue Breakthrough Therapy designation, file an NDA for MVID by mid-2027, and is in business development discussions to secure non-dilutive funding.
